myriamed supports COVID-19 research of the University Medical Center Göttingen (UMG)
We support the current research efforts on COVID-19 at the Institute of Pharmacology and Toxicology of the UMG by providing iPSC-derived cardiomyocytes (myrCell-Cardio) and specially designed multi-well plates (myrPlates) for culturing engineered human myocardium as a model system to identify potentially deadly cardiac disorders in patients with COVID-19 infections.
myriamed – the drug development accelerator
Separating the pharmacological wheat from the chaff is the primary goal of myriamed. Our proprietary human cell and engineered tissue models allow for the simulation of health and disease in the dish. Our platform technologies find broad applications in early stages of drug discovery and refinement of the most promising therapeutic candidates.
The availability of human cell and tissue models is transforming preclinical drug development. Applications range from early stages of lead discovery to advanced individualized phenotypic screens to shape a promising therapeutic candidate. myriamed offers a broad portfolio of highly standardized services as well as custom-made solutions to accelerate drug development.
At myriamed we focus on heart and skeletal muscle. Our myrCell and myrTissue platforms define wanted and unwanted drug effects in a unique human context. myrScreen combines our expertise in phenotypic drug screens and enables deep phenotyping of drug effects on healthy or diseased human heart and skeletal muscle.